Amylyx Pharmaceuticals, Inc. Annual Income Tax Expense (Benefit) in USD from 2022 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
Amylyx Pharmaceuticals, Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from 2022 to 2023.
  • Amylyx Pharmaceuticals, Inc. Income Tax Expense (Benefit) for the quarter ending March 31, 2024 was $242K.
  • Amylyx Pharmaceuticals, Inc. Income Tax Expense (Benefit) for the twelve months ending March 31, 2024 was $5.44M, a 1087% increase year-over-year.
  • Amylyx Pharmaceuticals, Inc. annual Income Tax Expense (Benefit) for 2023 was $5.03M, a 549% increase from 2022.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Annual (USD)
Income Tax Expense (Benefit), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $5.03M +$4.25M +549% Jan 1, 2023 Dec 31, 2023 10-K 2024-02-22
2022 $774K Jan 1, 2022 Dec 31, 2022 10-K 2024-02-22
* An asterisk sign (*) next to the value indicates that the value is likely invalid.